ArticleCancer biotherapy & radiopharmaceuticals2011
Imaging, autoradiography, and biodistribution of (188)Re-labeled PEGylated nanoliposome in orthotopic glioma bearing rat model.
Article in Cancer biotherapy & radiopharmaceuticals, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 30 citations in OpenAlex.
- Linking In Vivo Imaging to Therapeutic Outcome withInternational journal of molecular sciences · 2026Review
- LiposomalCancer science · 2025Article
- SapC-DOPS as a Novel Therapeutic and Diagnostic Agent for Glioblastoma Therapy and Detection: Alternative to Old Drugs and Agents.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Translating Research for the Radiotheranostics of NanotargetedInternational journal of molecular sciences · 2021Review
- Liposomes: Clinical Applications and Potential for Image-Guided Drug Delivery.Molecules (Basel, Switzerland) · 2018Review
- Locoregional Confinement and Major Clinical Benefit ofTheranostics · 2017Article
- Synthetic nanoparticles for delivery of radioisotopes and radiosensitizers in cancer therapy.Cancer nanotechnology · 2016Review
- Overview about the localization of nanoparticles in tissue and cellular context by different imaging techniques.Beilstein journal of nanotechnology · 2015Review
- Evaluation of 188Re-labeled PEGylated nanoliposome as a radionuclide therapeutic agent in an orthotopic glioma-bearing rat model.International journal of nanomedicine · 2015Article
- Image-guided interventional therapy for cancer with radiotherapeutic nanoparticles.Advanced drug delivery reviews · 2014Review
- The role of preclinical SPECT in oncological and neurological research in combination with either CT or MRI.European journal of nuclear medicine and molecular imaging · 2014Review
- Dawn of advanced molecular medicine: nanotechnological advancements in cancer imaging and therapy.Critical reviews in oncogenesis · 2014Review
- Nanomedicines for cancer therapy: state-of-the-art and limitations to pre-clinical studies that hinder future developments.Frontiers in chemistry · 2014Review
- In vitro and in vivo evaluation of lactoferrin-conjugated liposomes as a novel carrier to improve the brain delivery.International journal of molecular sciences · 2013Article
- Getting into the brain: liposome-based strategies for effective drug delivery across the blood-brain barrier.International journal of nanomedicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The (188)Re-labeled pegylated nanoliposome (abbreviated as (188)Re-Liposome) was prepared and evaluated for its potential as a theragnostic agent for glioma. (188)Re-BMEDA complex was loaded into the pegylated liposome core with pH 5.5 ammonium sulfate gradient to produce (188)Re-Liposome. Orthotopic Fischer344/F98 glioma tumor-bearing rats were prepared and intravenously injected with (188)Re-Liposome. Biodistribution, pharmacokinetic study, autoradiography (ARG), histopathology, and nano-SPECT/CT imaging were conducted for the animal model. The result showed that (188)Re-Liposome accumulated in the brain tumor of the animal model from 0.28%±0.09% injected dose (ID)/g (n=3) at 1 hour to a maximum of 1.95%±0.35% ID/g (n=3) at 24 hours postinjection. The tumor-to-normal brain uptake ratio (T/N ratio) increased from 3.5 at 1 hour to 32.5 at 24 hours. Both ARG and histopathological images clearly showed corresponding tumor regions with high T/N ratios. Nano-SPECT/CT detected a very clear tumor image from 4 hours till 48 hours. This study reveals the potential of (188)Re-Liposome as a theragnostic agent for brain glioma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.